Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA ligase 3 is a vertebrate-specific enzyme crucial for sealing nicks in DNA during replication and multiple DNA repair pathways, including base excision, nucleotide excision, and single-strand break repair in both nuclear and mitochondrial compartments. Its structure features a unique N-terminal zinc finger that enhances DNA end recognition and binding. In the nucleus, it operates mainly as a complex with XRCC1, and in mitochondria, it is essential for genome maintenance. Ligase 3 becomes particularly important in cells where canonical NHEJ is impaired, facilitating an alternative repair pathway. It is frequently overexpressed in various cancers, where it promotes survival by maintaining DNA repair capacity, making it a promising therapeutic target.
Inhibitors would block the catalytic activity of DNA ligase 3, preventing DNA strand rejoining and leading to accumulation of DNA strand breaks, genomic instability, and cell death, especially in cancer cells dependent on alternative NHEJ. Potential for synthetic lethality when combined with inhibitors of other DNA repair proteins.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA ligase 3 (DNA ligase III (LIG3)).